Tumour escape from immune surveillance through dendritic cell inactivation.

by: AP Vicari, C Caux, G Trinchieri

Semin Cancer Biol, Vol. 12, No. 1. (February 2002), pp. 33-42.

View FullText article

DOI, Pubmed, Hubmed

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

AlfonsoVicenteSuarez

Find related articles with these CiteULike tags

tolerogenic-dcs

Abstract

Dendritic cells (DC) are central to the initiation of immunity. To induce immune reactivity, DC are recruited at the site of antigen expression, uptake antigens and migrate to secondary lymphoid organs while receiving activation signals delivered by pathogens, dying cells, and/or T cells. Tumours can escape the immune system by interfering with the migration of DC or by not providing the necessary activation signals. Moreover, tumours promote the secretion of factors that inhibit DC differentiation and functions. We will review the current knowledge of the physiopathology of DC in cancer, which paves the way for novel strategies of therapeutic intervention.

@article{citeulike:1387960, abstract = {Dendritic cells (DC) are central to the initiation of immunity. To induce immune reactivity, DC are recruited at the site of antigen expression, uptake antigens and migrate to secondary lymphoid organs while receiving activation signals delivered by pathogens, dying cells, and/or T cells. Tumours can escape the immune system by interfering with the migration of DC or by not providing the necessary activation signals. Moreover, tumours promote the secretion of factors that inhibit DC differentiation and functions. We will review the current knowledge of the physiopathology of DC in cancer, which paves the way for novel strategies of therapeutic intervention.}, address = {Schering-Plough Research Institute, Laboratory for Immunological Research, Dardilly, France. alain.vicari@spcorp.com}, author = {Vicari, A. P. and Caux, C. and Trinchieri, G. }, citeulike-article-id = {1387960}, doi = {10.1006/scbi.2001.0400}, issn = {1044-579X}, journal = {Semin Cancer Biol}, keywords = {tolerogenic-dcs}, month = {February}, number = {1}, pages = {33--42}, posted-at = {2007-06-13 18:45:19}, priority = {2}, title = {Tumour escape from immune surveillance through dendritic cell inactivation.}, url = {http://dx.doi.org/10.1006/scbi.2001.0400}, volume = {12}, year = {2002} }

RIS record

TY - JOUR ID - citeulike:1387960 TI - Tumour escape from immune surveillance through dendritic cell inactivation. JF - Semin Cancer Biol VL - 12 IS - 1 SP - 33 EP - 42 AD - Schering-Plough Research Institute, Laboratory for Immunological Research, Dardilly, France. alain.vicari@spcorp.com SN - 1044-579X N2 - Dendritic cells (DC) are central to the initiation of immunity. To induce immune reactivity, DC are recruited at the site of antigen expression, uptake antigens and migrate to secondary lymphoid organs while receiving activation signals delivered by pathogens, dying cells, and/or T cells. Tumours can escape the immune system by interfering with the migration of DC or by not providing the necessary activation signals. Moreover, tumours promote the secretion of factors that inhibit DC differentiation and functions. We will review the current knowledge of the physiopathology of DC in cancer, which paves the way for novel strategies of therapeutic intervention. KW - tolerogenic-dcs AU - Vicari, AP AU - Caux, C AU - Trinchieri, G PY - 2002/02// UR - http://dx.doi.org/10.1006/scbi.2001.0400 ER -

RIS BibTeX